Cover Image
市場調查報告書

第三型黏多糖症(MPSⅢ)(聖菲利柏氏症): 全球臨床實驗檢討

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 304744
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
第三型黏多糖症(MPSⅢ)(聖菲利柏氏症): 全球臨床實驗檢討 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Global Clinical Trials Review, H2, 2017
出版日期: 2017年12月28日 內容資訊: 英文 47 Pages
簡介

本報告提供第三型黏多糖症(MPSⅢ)相關的臨床研究最新趨勢分析,提供疾病·治療方法概要,並彙整臨床實驗的主要國家,G7各國及E7(新興7國)的臨床實驗數及實驗對象採用狀況,地區、PHASE、階段別的進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

目錄

簡介

  • 第三型黏多糖症(MPSⅢ)(聖菲利柏氏症)
  • 本報告概要

各地區的臨床實驗情形

各國臨床實驗數量和平均實驗人數

  • 歐洲前五名國家的臨床實驗數量
  • 北美主要國家的臨床實驗數量
  • 中南美前五名國家的臨床實驗數量

G7各國臨床實驗數量:代謝性疾病臨床實驗數量中,第三型黏多糖症(MPSⅢ)的比率

G7各國臨床實驗數量:Phase別

G7各國臨床實驗數量:各進展狀況

E7(新興7個國家)的臨床實驗數量:代謝性疾病臨床實驗數量中,第三型黏多糖症(MPSⅢ)的比率

Phase別臨床實驗數量

  • 進行中的臨床實驗:不同階段

各進展狀況臨床實驗數量

試驗指標達成狀況別臨床實驗數量

尚未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

有潛力的藥劑

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • Shire Plc
    • UniQure NV
    • Lysogene
    • Synageva BioPharma Corp.
    • Cytomedix, Inc.
    • BioMarin Pharmaceutical Inc.
  • 有代表性的研究機關·醫院臨床實驗概要
    • Academic Medical Center
    • Masonic Cancer Center
    • The University of Manchester
    • The University of Chicago
    • Hospices Civils de Lyon
    • University of Louisville
    • University of Minnesota

5個有代表性的臨床實驗簡介

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4804CTIDB

GlobalData's clinical trial report, "Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Global Clinical Trials Review, H2, 2017" provides an overview of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) clinical trials scenario. This report provides top line data relating to the clinical trials on Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) to Genetic Disorders Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) to Genetic Disorders Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials by Phase 19
  • In Progress Trials by Phase 20
  • Clinical Trials by Trial Status 21
  • Clinical Trials by End Point Status 22
  • Subjects Recruited Over a Period of Time 23
  • Clinical Trials by Sponsor Type 24
  • Prominent Sponsors 25
  • Top Companies Participating in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials 26
  • Prominent Drugs 27
  • Clinical Trial Profile Snapshots 28

Appendix 45

  • Abbreviations 45
  • Definitions 45
  • Research Methodology 46
  • Secondary Research 46
  • About GlobalData 47
  • Contact Us 47
  • Source 47

List of Tables

List of Tables

  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 10
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 13
  • Proportion of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 14
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Proportion of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 17
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials by Phase, 2017* 19
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 20
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 21
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 22
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 23
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 24
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 25
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 26
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 27
Back to Top